RSS

pre-clinical data

Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL). more

News

Developer of placenta-based cell therapy products, Pluristem Therapeutics, has revealed that its PLX cells have been shown to significantly inhibit cancer cell growth in a recently published peer-reviewed article. more

News

Clinical-stage biopharmaceutical company, Autolus, has announced the publication of pre-clinical data of a novel, dual-targeted, proliferating-inducing ligand (APRIL) chimeric antigen receptor (CAR) for the treatment of multiple myeloma. more

News